This stock is not for the impatient
After the late-stage failures of the oral mucositis drugs of Oragenics, Soligenix and Galera, IMO, no company is going to be willing to RISK the many million$ it would take to finance a B-OM/P-3. IPIX has no funds for clinical trials and B-OM will just have to rest on the backburner until they do.
The licensing agreement with Alfasigma " to develop and commercialize locally-administered Brilacidin (e.g., foam, enema, gel), on a worldwide basis, for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS)" shows no signs of providing any significant financial gain to IPIX any time soon. This agreement was signed 4 years ago come July 2023.
NIH/NIAID and their proxies, as well as foreign entities, are investigating the scope of brilacidin's antiviral/antifungal capabilities and synergism with other drugs. IMO, it will probably be a year or two before any clinical trial(s) is announced in any of these areas. Candida Auris, while present in more than half of the 50 U.S. states, IMO, is not yet a big enough problem to warrant emergency action allowing for brilacidin to be used in combination with another drug based on invitro testing only. This, however, could rapidly change.
In January 2023, BeaMed signed a MULTIYEAR DEVELOPMENT AND SUPPORT AGREEMENT with Shina Systems, LTD. This suggest that, despite the possibility for quick FDA approval, BeaMed's next-generation laser based platform for epilepsy and cancer surgery is still a year or two away from market introduction.
IMO, BeaMed excluded, IPIX is not in the right position to be sold or partnered. I think a potential partner or buyer would see too much risk and would probably think there are better places to invest their capital. Additionally, I believe Leo has probably already fielded and rejected low-ball offers for indications or the company and, IMO, he has been very selective about the deals he makes.
Personally, I am heartened by all of this because I believe Leo will, ultimately, be successful in negotiating this long and winding road to success. I am also heartened by the negativity toward Leo and this stock in that I believe it has a depressing effect on IPIX's stock price, allowing me to continue to accumulate at these fire sale prices.
Yes, this is not a stock for the impatient, but for those who see what I see, it is a stock for the opportunistic.
Bullish
